Dexcom’s Jake Leach Named Chair of AdvaMed’s Diabetes Sector

WASHINGTON—AdvaMed, the MedTech Association®, today announced that Jacob “Jake” Leach, President and Chief Executive Officer at Dexcom, will serve as the next chair of theAdvaMed® Diabetes Sector, succeeding Chris Scoggins, Executive Vice President of Diabetes Care at Abbott. The AdvaMed Diabetes Sector represents the world’s leading companies producing technology across the spectrum of diabetes care. 

“Jake brings decades of experience advancing patient-centered diabetes care and driving innovation across the medtech industry,” said Scott Whitaker,AdvaMed® President and CEO. “The AdvaMed Diabetes Sector plays a critical role in advocating for policies that expand access to diabetes technologies, improve patient outcomes, and support equitable care for all patients. Thank you, Jake, for your willingness to lead in this important role.” 

Whitaker also expressed gratitude to Scoggins for his leadership. “Chris led the AdvaMed Diabetes Sector with a clear focus on the patients and families who depend on these technologies every day,” Whitaker said. “At a time of rapid innovation and important policy conversations around access and affordability, his leadership helped strengthen our voice and advance solutions that empower people with diabetes to live healthier, fuller lives.”  

Eric Benjamin, Executive Vice President and Chief Operating Officer at Insulet, will serve as the sector’s vice chair. 

Leach has spent nearly 22 years at Dexcom, helping grow the company from 30 employees to more than 10,000 worldwide. Under his leadership, Dexcom has expanded access to diabetes management tools and partnered with consumer tech companies and public figures to raise awareness of diabetes care.  

“It is an honor to serve as chair of theAdvaMed® Diabetes Sector,” Leach said. “I look forward to collaborating with the diabetes sector member companies to advance innovation in diabetes care, ensure people can access life-changing technologies, and continue advocating for policies that prioritize health outcomes.” 

TheAdvaMed® Diabetes Sector advocates for policies that support the 40 million Americans living with diabetes and the 115 million Americans living with prediabetes by developing innovative medtech that empowers patients with real-time data, alerts, and insights to manage their health and prevent serious complications through early detection and intervention. 

AdvaMed diabetes sector member companies cover the range of care across the diabetes ecosystem, including technologies that help prevent, diagnose, treat, monitor, and manage the complications of diabetes. These companies include: Abbott, Ascensia Diabetes Care, Baxter International Inc., Boston Scientific Corporation, Bruin Biometrics, Cardinal Health, CeQur, Dexcom, Digital Diagnostics, Eli Lilly and Company, embecta, Endogenex, Glooko, Humacyte, Inc., Ideal Medical Technologies, Indigo Diabetes NV, Insulet, Johnson & Johnson MedTech, Medtronic, Morphic Medical, Novo Nordisk, Philips, Phoenix NeuroStim Therapeutics, Podimetrics, Roche Diagnostics, Senseonics, Siemens Healthineers, Siren Care, Inc., Tandem Diabetes Care, Inc., and Verily Life Sciences. 

###